# US 10,369,174 B2 · Pharmaceutical composition for preventing or treating metabolic diseases, comprising bacteroides acidifaciens as active ingredient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,369,174 B2
- Document ID: US10369174B2
- Status: Granted
- Kind: B2
- Application number: 15/534,068
- Filed: 2015-12-08
- Published: 2017-11-23
- Granted: 2019-08-06
- Earliest claimed: 2014-12-08
- Assignees: Gi Biome
- Applicants: The Asan Foundation
- Inventors: Mi Na Kweon; Jin Young Yang
- Web page: https://patentgrep.com/patent/US10369174B2

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A23L 33/30: {Dietetic or nutritional methods, e.g. for losing weight (A23L33/10 takes precedence)}
- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A61K 35/66: Microorganisms or materials therefrom (fungi, yeasts or candida A61K36/06)
- A61K 38/1709: {from mammals}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/48: of the pancreatic hormones
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The present disclosure relates to a composition for preventing or treating metabolic diseases, in which the composition includes Bacteroides acidifaciens as an active ingredient. In addition, the present disclosure relates to a composition for oxidizing fat or inhibiting DPP-4, in which the composition includes Bacteroides acidifaciens as an active ingredient. In addition, the present disclosure relates to a transformant expressing a lean phenotype, in which an Atg7 gene is deleted in dendritic cells.

## Claims

### Claim 1

A method for treating obesity in a subject, the method comprising administering a pharmaceutically-effective amount of Bacteroides acidifaciens to the subject in need of treatment of obesity.

### Claim 2 (depends on 1)

A method for treating obesity according to claim 1, wherein the Bacteroides acidifaciens activates fat oxidation in adipose tissue.

### Claim 3 (depends on 1)

A method for treating obesity according to claim 1, wherein the subject administered the pharmaceutically-effective amount of Bacteroides acidifaciens has a higher amount of intestinal total bacteria as compared to an obese person not administered the pharmaceutically-effective amount of Bacteroides acidifaciens.